$1.01
+0.00 (+0.00%)
Open$1.00
Previous Close$1.01
Day High$1.03
Day Low$0.99
52W High$1.45
52W Low$0.70
Volume—
Avg Volume664.9K
Market Cap42.51M
P/E Ratio—
EPS$-0.44
SectorBiotechnology
Analyst Ratings
Strong Buy
10 analysts
Price Target
+3,607.9% upside
Current
$1.01
$1.01
Target
$37.45
$37.45
$24.30
$37.45 avg
$44.03
Key Financials
| FY 2026 | FY 2025 | FY 2024 | |
|---|---|---|---|
| Revenue | 73.4K | 3.79M | 3.81M |
| Net Income | -15,297,274 | 783.4K | 928.9K |
| Profit Margin | -20,497.7% | 20.7% | 24.4% |
| EBITDA | -15,962,037 | 1.80M | 1.92M |
| Free Cash Flow | — | 820.9K | 949.0K |
| Rev Growth | — | +6.9% | +13.5% |
| Debt/Equity | — | 0.92 | 0.74 |
Biotechnology Peers
| Symbol | Name | Price | Change | P/E | Mkt Cap |
|---|---|---|---|---|---|
| ABBV | Abbvie Inc | $214.98 | -1.15% | 166.6 | 397.77B |
| AMGN | Amgen Inc | $353.28 | +0.41% | 24.7 | 190.40B |
| GILD | Gilead Sciences Inc | $140.30 | +0.67% | 19.6 | 166.66B |
| VRTX | Vertex Pharmaceuticals Inc | $447.26 | +0.16% | 29.1 | 114.87B |
| REGN | Regeneron Pharmaceuticals | $777.25 | +0.60% | 17.9 | 80.50B |
| ALNY | Alnylam Pharmaceuticals Inc | $328.73 | -0.65% | 139.7 | 43.84B |